Lp(a): The Genetic Cardiovascular Risk Factor Most People Have Never Heard Of
Lipoprotein(a) - Lp(a) - is an LDL-like particle with an additional protein (apolipoprotein(a)) that makes it uniquely dangerous. It is almost entirely genetically determined, present at elevated levels in approximately 20 percent of the population, and one of the most powerful independent cardiovascular risk factors ever identified. Most people have never had it measured. Most physicians never order it. This needs to change.
- Lp(a) consists of an LDL-like particle covalently bound to apolipoprotein(a) - a protein with structural similarity to plasminogen that gives Lp(a) its unique pro-thrombotic and pro-inflammatory properties in addition to its atherogenic properties. This triple threat makes elevated Lp(a) uniquely dangerous compared to elevated LDL alone.
- Lp(a) levels are 80 to 90 percent genetically determined - primarily by the LPA gene locus - and are largely unresponsive to diet, exercise, or standard lipid-lowering medications including statins. This is both the clinical challenge and the reason that one-time testing is generally sufficient: the number does not change meaningfully with lifestyle.
- Elevated Lp(a) (above 50 mg/dL or 125 nmol/L) is present in approximately 20 percent of the population and is associated with 2 to 4 times elevated risk of myocardial infarction, 2 to 3 times elevated risk of aortic valve stenosis, and elevated stroke risk - independent of LDL-C, ApoB, and all other cardiovascular risk factors.
- The current standard of care for elevated Lp(a) is aggressive management of all other modifiable cardiovascular risk factors - particularly LDL-C, blood pressure, glucose, smoking, and inflammation - since Lp(a) itself cannot yet be meaningfully lowered pharmacologically. RNA-based therapies specifically targeting Lp(a) are in late-stage clinical trials and represent the most promising therapeutic horizon.
- Lp(a) should be measured once in every adult as part of a complete cardiovascular risk assessment. It is available at most commercial labs for under 30 dollars. The result is reported in either mg/dL or nmol/L - ensure you know which unit your lab is using, as the conversion is not 1:1.
Lipoprotein(a) was first described by Kare Berg in 1963. For the following four decades, it occupied an uncomfortable position in cardiovascular medicine: clearly associated with cardiovascular risk in observational studies, but lacking a mechanism that distinguished it from LDL and lacking any pharmacological intervention to lower it. Mendelian randomization studies published from 2009 onward definitively established that elevated Lp(a) is causally - not merely associatively - linked to cardiovascular disease. A new class of RNA-targeting therapeutics capable of lowering Lp(a) by 80 to 95 percent has since entered late-stage clinical trials. The era of Lp(a) as an untreatable risk factor is ending.1
What Makes Lp(a) Uniquely Dangerous
Lp(a) is an LDL-like particle - it contains an ApoB-100 core surrounded by phospholipids and cholesterol esters - with an additional large protein called apolipoprotein(a) [apo(a)] covalently attached via a disulfide bond. The apo(a) protein has a domain structure resembling plasminogen, the precursor to the fibrinolytic enzyme plasmin that dissolves blood clots. This structural mimicry allows Lp(a) to compete with plasminogen for fibrin binding, inhibiting clot dissolution and promoting thrombosis - a mechanism completely distinct from LDL's atherosclerotic risk.2
The result is a particle with three distinct pathological mechanisms operating simultaneously: atherogenesis (via ApoB-mediated arterial wall penetration and foam cell formation), thrombogenesis (via apo(a) plasminogen competition), and inflammation (Lp(a) carries oxidized phospholipids that activate inflammatory pathways in arterial walls). This triple threat explains why elevated Lp(a) is more dangerous per particle than elevated LDL alone - and why standard lipid-lowering strategies that target LDL do not adequately address Lp(a) risk.
The Genetic Architecture: Why Lifestyle Does Not Change It
Lp(a) levels are determined primarily by variation at the LPA gene locus on chromosome 6q27. The LPA gene encodes apo(a), and variation in the number of kringle IV type 2 (KIV-2) repeat sequences within the gene is the primary determinant of Lp(a) levels: individuals with fewer KIV-2 repeats produce smaller apo(a) isoforms that are more efficiently secreted by the liver, resulting in higher circulating Lp(a). The heritability of Lp(a) levels is estimated at 80 to 90 percent.3
The clinical implication: Lp(a) is essentially immutable with currently available interventions. Statins - the most potent available LDL-lowering drugs - do not lower Lp(a) and may modestly increase it. Exercise, diet, weight loss, and other lifestyle interventions have minimal effects on Lp(a) levels. Niacin lowers Lp(a) modestly (20 to 30 percent) but fell out of clinical use after the AIM-HIGH and HPS2-THRIVE trials found no cardiovascular benefit and significant side effects. This is why measuring Lp(a) once is generally sufficient - the result will not change meaningfully with any available intervention.
What to Do With an Elevated Lp(a)
The current strategy for managing elevated Lp(a) is aggressive risk factor modification for all other modifiable cardiovascular risk factors. Since Lp(a) cannot be meaningfully lowered with available medications, the goal is to reduce the overall atherogenic and thrombogenic burden such that the Lp(a) contribution is operating against the lowest possible background risk. This means: achieving an LDL-C below 70 mg/dL (or ApoB below 60 mg/dL) - possibly requiring statin plus ezetimibe plus PCSK9 inhibitor in high-Lp(a) individuals; optimal blood pressure control; aggressive glycemic management; complete smoking cessation; and anti-inflammatory lifestyle optimization (exercise, Mediterranean diet, omega-3 supplementation).4
The Therapeutic Horizon: RNA-Based Lp(a) Lowering
Two RNA-targeting therapeutic approaches - antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) - have demonstrated 80 to 95 percent reductions in Lp(a) levels in Phase 2 trials. Pelacarsen (an ASO targeting LPA mRNA) reduced Lp(a) by 80 percent in the Phase 2 ATLAS trial and is in a Phase 3 cardiovascular outcomes trial (HORIZON). Olpasiran (a siRNA targeting LPA) reduced Lp(a) by 95 percent in Phase 2 studies. If the ongoing Phase 3 trials demonstrate cardiovascular event reduction with Lp(a) lowering, this would be a landmark in cardiovascular medicine - confirming causality and establishing a new therapeutic target with a highly effective drug class.5
Put this research into practice: Gene Variant Lookup · Biomarker Reference Tool · What Should I Test Next?
References
- 1Clarke R, et al. "Genetic variants associated with Lp(a) lipoprotein level and coronary disease." N Engl J Med. 2009;361(26):2518-28. PubMed · DOI
- 2Tsimikas S. "A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies." J Am Coll Cardiol. 2017;69(6):692-711. PubMed · DOI
- 3Boerwinkle E, et al. "Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations." J Clin Invest. 1992;90(1):52-60. PubMed · DOI
- 4Grundy SM, et al. "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines." J Am Coll Cardiol. 2019;73(24):e285-e350. PubMed · DOI
- 5Tsimikas S, et al. "Lipoprotein(a) Reduction in Persons with Cardiovascular Disease." N Engl J Med. 2020;382(3):244-255. PubMed · DOI